PCSK‐9 Inhibitors Can Significantly Improve the Coronary Slow Flow Caused by Elevated Lipoprotein (a) in ST‐Elevation Myocardial Infarction Patients With Chronic Kidney Disease
Elevated Lp(a) is an independent risk factor for coronary slow flow or no reflow after PCI in STEMI patients with CKD. PCSK-9 inhibitors improve coronary blood flow and reduce cardiovascular events in these patients.
Authors
- Hao Xu (ORCID: https://orcid.org/0000-0002-2487-9668)
- Junhua Ge (ORCID: https://orcid.org/0000-0002-3119-6478)
- Dan Chen (ORCID: https://orcid.org/0000-0002-7055-141X)
- Ziqing Wang (ORCID: https://orcid.org/0009-0000-4702-4681)
- Jian Li (ORCID: https://orcid.org/0000-0003-2075-0119)
- H Zhang
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- Catheterization and Cardiovascular Interventions
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1002/ccd.31543
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Natural Science Foundation of Shandong Province